Target family: Inwardly rectifying potassium channels (K<sub>IR</sub>) (type: vgic)
Target: K<sub>ir</sub>3.4

Ligand: amitriptyline (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1961)
Median affinity: 3.6 pIC50
Reference (Journal): Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
Published in: Neuropsychopharmacology

Ligand: arachidonic acid (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Median affinity:  -
Reference (Journal): G-protein beta gamma-subunits activate the cardiac muscarinic K+-channel via phospholipase A2.
Published in: Nature

Ligand: AZD2927 (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: yes
Median affinity: 5.900000095367432 pIC50
Reference (Webpage): AZD2927.

Ligand: Ba2+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 3.3 pEC50
Reference (Journal): The G-protein-gated atrial K+ channel IKACh is a heteromultimer of two inwardly rectifying K(+)-channel proteins.
Published in: Nature

Ligand: clomipramine (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1989)
Median affinity: 3.6 pIC50
Reference (Journal): Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
Published in: Neuropsychopharmacology

Ligand: Cs+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 4 pEC50
Reference (Journal): The G-protein-gated atrial K+ channel IKACh is a heteromultimer of two inwardly rectifying K(+)-channel proteins.
Published in: Nature

Ligand: desipramine (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (no history prior to 1964)
Median affinity: 4.3 pIC50
Reference (Journal): Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
Published in: Neuropsychopharmacology

Ligand: ethanol (Metabolite)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Ethanol opens G-protein-activated inwardly rectifying K+ channels.
Published in: Nat Neurosci

Ligand: ethanol (Metabolite)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action.
Published in: Nat Neurosci

Ligand: fingolimod (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: yes
Approval source: FDA (2010), EMA (2011)
Median affinity:  -
Reference (Journal): The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I.
Published in: Am J Transplant

Ligand: imipramine (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1959)
Median affinity: 4.5 pEC50
Reference (Journal): Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
Published in: Neuropsychopharmacology

Ligand: maprotiline (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1980)
Median affinity: 3.5 pIC50
Reference (Journal): Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
Published in: Neuropsychopharmacology

Ligand: Na+ (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Median affinity: 1.4 pEC50
Reference (Journal): Na+ activation of the muscarinic K+ channel by a G-protein-independent mechanism.
Published in: J Gen Physiol

Ligand: NIP-142 (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Median affinity:  -
Reference (Journal): Atria selective prolongation by NIP-142, an antiarrhythmic agent, of refractory period and action potential duration in guinea pig myocardium.
Published in: J Pharmacol Sci

Ligand: nortriptyline (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1964)
Median affinity: 3.4 pIC50
Reference (Journal): Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
Published in: Neuropsychopharmacology